Anthony M. Hunter

764 total citations
41 papers, 326 citations indexed

About

Anthony M. Hunter is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Anthony M. Hunter has authored 41 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 26 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Anthony M. Hunter's work include Acute Myeloid Leukemia Research (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers) and Chronic Myeloid Leukemia Treatments (14 papers). Anthony M. Hunter is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers) and Chronic Myeloid Leukemia Treatments (14 papers). Anthony M. Hunter collaborates with scholars based in United States, Italy and France. Anthony M. Hunter's co-authors include David A. Sallman, Eric Padron, Rami S. Komrokji, Ling Zhang, Chetasi Talati, Jeffrey E. Lancet, Najla Al Ali, Kendra Sweet, David J. Stewart and Alan F. List and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Anthony M. Hunter

34 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anthony M. Hunter United States 10 254 134 119 48 34 41 326
Jörg Chromik Germany 7 279 1.1× 150 1.1× 109 0.9× 40 0.8× 21 0.6× 16 354
Patrick Löffeld Germany 2 255 1.0× 123 0.9× 189 1.6× 18 0.4× 27 0.8× 3 325
Li Ye China 8 195 0.8× 73 0.5× 76 0.6× 40 0.8× 25 0.7× 36 237
Shiqiang Qu China 12 295 1.2× 211 1.6× 116 1.0× 28 0.6× 25 0.7× 45 365
Bartlomiej Getta United States 6 184 0.7× 117 0.9× 64 0.5× 31 0.6× 24 0.7× 19 236
Samuel Quentin France 7 182 0.7× 87 0.6× 132 1.1× 39 0.8× 21 0.6× 9 288
Sophie Dobbelstein France 6 168 0.7× 80 0.6× 101 0.8× 68 1.4× 31 0.9× 7 261
Friederike Pastore Germany 8 255 1.0× 131 1.0× 164 1.4× 23 0.5× 9 0.3× 12 303
J. Maciejewski United States 7 259 1.0× 107 0.8× 180 1.5× 30 0.6× 30 0.9× 10 345
Chandrakala Shanmukhaiah India 11 228 0.9× 140 1.0× 93 0.8× 18 0.4× 12 0.4× 53 319

Countries citing papers authored by Anthony M. Hunter

Since Specialization
Citations

This map shows the geographic impact of Anthony M. Hunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony M. Hunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony M. Hunter more than expected).

Fields of papers citing papers by Anthony M. Hunter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony M. Hunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony M. Hunter. The network helps show where Anthony M. Hunter may publish in the future.

Co-authorship network of co-authors of Anthony M. Hunter

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony M. Hunter. A scholar is included among the top collaborators of Anthony M. Hunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony M. Hunter. Anthony M. Hunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duan, Minghui, Prithviraj Bose, Anthony M. Hunter, et al.. (2025). Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera. Current Hematologic Malignancy Reports. 20(1). 13–13.
2.
Abu‐Zeinah, Ghaith, Anthony M. Hunter, Joseph J. Shatzel, et al.. (2025). Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients. PubMed. 2(4). 100167–100167.
3.
4.
Atallah, Ehab, Michael S. Broder, Onyee Chan, et al.. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. 144(Supplement 1). 5052–5052.
5.
Watts, Justin M., Alessandro M. Vannucchi, Anthony M. Hunter, et al.. (2024). Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.. Journal of Clinical Oncology. 42(16_suppl). 6576–6576. 1 indexed citations
6.
Hunter, Anthony M., Mrinal M. Patnaik, Raphaël Itzykson, et al.. (2024). Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm. Blood. 144(19). 1987–1992. 4 indexed citations
7.
Cherian, Sajeev, et al.. (2024). A Case Series on Post Essential Thrombocytosis Myelofibrosis Conversion to Chronic Myeloid Leukemia. Blood. 144(Supplement 1). 6613–6613.
8.
Hunter, Anthony M., et al.. (2024). SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia. 25(4). 226–239.
9.
10.
11.
12.
Ferrall‐Fairbanks, Meghan C., Brian Johnson, Christopher T. Letson, et al.. (2022). Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discovery. 3(6). 536–553. 9 indexed citations
13.
Hunter, Anthony M., Terra L. Lasho, Christy M. Finke, et al.. (2022). Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia. 36(6). 1693–1696. 2 indexed citations
14.
Brunner, Andrew M., Najla Al Ali, Anthony M. Hunter, et al.. (2022). Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer Journal. 12(11). 153–153. 5 indexed citations
15.
Hunter, Anthony M. & Eric Padron. (2021). Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports. 16(3). 247–255. 4 indexed citations
16.
Hunter, Anthony M., Najla Al Ali, Andrew Kuykendall, et al.. (2021). Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leukemia Research. 109. 106640–106640. 10 indexed citations
17.
Hunter, Anthony M. & Eric Padron. (2020). Molecular genetics of MDS/MPN overlap syndromes. Best Practice & Research Clinical Haematology. 33(3). 101195–101195. 5 indexed citations
18.
Coltro, Giacomo, Abhishek A. Mangaonkar, Terra L. Lasho, et al.. (2019). Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients. Leukemia. 34(5). 1407–1421. 63 indexed citations
19.
Hunter, Anthony M. & David A. Sallman. (2019). Targeting TP53 Mutations in Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America. 34(2). 421–440. 13 indexed citations
20.
Hunter, Anthony M. & David A. Sallman. (2019). Current status and new treatment approaches in TP53 mutated AML. Best Practice & Research Clinical Haematology. 32(2). 134–144. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jörg Chromik Breakdown of academic impact, for papers by Patrick Löffeld Breakdown of academic impact, for papers by Li Ye Breakdown of academic impact, for papers by Shiqiang Qu Breakdown of academic impact, for papers by Bartlomiej Getta Breakdown of academic impact, for papers by Samuel Quentin Breakdown of academic impact, for papers by Sophie Dobbelstein Breakdown of academic impact, for papers by Friederike Pastore Breakdown of academic impact, for papers by J. Maciejewski Breakdown of academic impact, for papers by Chandrakala Shanmukhaiah
Rankless by CCL
2026